Chronic lymphocytic leukemia (CLL) is accompanied by increased risk of potentially fatal infections. While this can mostly be attributed to disease-related immune dysfunction, it is not known if CLL patients are also constitutionally susceptible to infections. We linked nation-wide Danish registers to explore this possibility, approximating infection susceptibility by use of antimicrobials. We assessed the incidence of antimicrobials among CLL patients and matched controls from the general population for up to 22 years before index diagnosis, and among children and grandchildren of CLL patients and their matched controls. Our analyses showed that for CLL patients overall antimicrobial use began to increase gradually six years before leukemia diagnosis. Before this time point, CLL patients had used significantly more macrolides (relative risk = 1.15; 95% confidence interval 1.10–1.20), antimycotics (1.18; 1.08–1.30), and antivirals (1.62; 1.45–1.81) than controls for up to 22 years before diagnosis. The same pattern of increased use was found among CLL patients’ children and grandchildren. Our study suggests that CLL diagnosis is preceded by decades of increased susceptibility to infections. The duration of this time window is compatible with causal roles of immune dysfunction and/or certain infections in CLL pathogenesis, possibly mediating the association between constitutional infection susceptibility and CLL risk.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wang J, Khiabanian H, Rossi D, Fabbri G, Gattei V, Forconi F, et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife. 2014;3:1–23.
Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009;360:659–67.
Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136–41.
Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol. 2009;147:444–9.
Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139:791–8.
Landgren O, Rapkin JS, Caporaso NE, Mellemkjaer L, Gridley G, Goldin LR, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109:2198–201.
Rasmussen M-L, Hjalgrim H, Mølgaard-Nielsen D, Wohlfahrt J, Melbye M. Antibiotic use and risk of non-Hodgkin lymphomas. Int J Cancer. 2012;131:E1158–65.
Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun. 2017;8:1–12.
Rostgaard K. Methods for stratification of person-time and events—a prerequisite for Poisson regression and SIR estimation. Epidemiol Perspect Innov. 2008;5:1–16.
Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114:4928–32.
Andersen M, Grand M, Siersma V, Andersen C, Niemann C. Prediagnostic trajectories of hemoglobin, lymphocyte and platelet count in patients developing CLL. HemaSphere. 2019;3:853–4.
Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematol Am Soc Hematol Educ Program. 2005;2005:231–8.
Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, et al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood. 2018;131:2541–51.
Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010;151:152–8.
Casabonne D, Almeida J, Nieto WG, Romero A, Fernández-Navarro P, Rodriguez-Caballero A, et al. Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. PLoS One. 2012;7:1–8.
This work is supported in part by the Research Foundation of Rigshospitalet, Neye Foundation [26-9-2019], Ulla and Mogens Folmer Andersens Foundation [100041-1] and Danish National Research Foundation [grant 126]. CUN is supported by Novo Nordisk Foundation grant [NNF16OC0019302].
Danish registry data can be obtained through application to the relevant data agencies. Analytical methods and source code will be made available on request to corresponding author.
Conflict of interest
CUN received funding from the Danish Cancer Society and the Novo Nordisk Foundation (NNF16OC0019302), and received grants/consultancy fees from AbbVie, Janssen, Gilead, AstraZeneca, Acerta, CSL Behring Roche and Novartis outside of this study. MAA, HH, and KR report no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Andersen, M.A., Rostgaard, K., Niemann, C.U. et al. Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study. Leukemia 35, 747–751 (2021). https://doi.org/10.1038/s41375-020-0980-0